Brind.

Leerink partners maintained a Buy rating on United Therapeutics stock on July 28, 2025.

1 report, 1 independent Updated Jul 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

United Therapeutics Leerink partners

Keep exploring

The entities involved

United Therapeutics
biotech company based in Silver Spring, Maryland, United States

Nothing else this week.
Leerink partners
U.S. investment bank
- Illumina and Leerink partners are involved in a new development.Mon 15:26
- Leerink Partners reduced its target price for Keros Therapeutics on November 2, 2026.Mon 11:50

Coverage

Newest first; wire copies grouped

Jul 28Insider MonkeyLeerink Partners Remains a Buy on United Therapeutics Corporation (UTHR) With a $408 PT United Therapeutics Corporation (NASDAQ:UTHR) is one of the most profitable biotech stocks to invest in now. In